Literature DB >> 20188638

Patients with cystic fibrosis and normoglycemia exhibit diabetic glucose tolerance during pulmonary exacerbation.

Noa Nezer M Sc1, David Shoseyov, Eitan Kerem, David Haim Zangen.   

Abstract

BACKGROUND: Patients with cystic fibrosis and normoglycemia (CF-NGT) have higher but still "normal" glucose levels in the Oral Glucose Tolerance Test (OGTT). Respiratory exacerbation is associated with metabolic stress. The objective of this study was to assess the glucose metabolism and its relation to the steady state pulmonary function (FEV1) in patients with CF-NGT, specifically during pulmonary exacerbations (PE).
METHODS: CF-NGT patients who were not on steroids, underwent OGTT and intravenous glucose tolerance tests (IVGTT) during PE and 4weeks after complete recovery.
RESULTS: Of the ten recruited patients two had diabetic OGTT and were excluded. The remaining normoglycemic patients displayed during PE a diabetic glucose tolerance with mean glucose levels of 233+/-8 and 262+/-11mg/dl at 90 and 120min respectively, compared with normal levels of 154+/-21and 126+/-20mg/dl (p<0.002) during the steady state. IVGTT showed a tendency to higher first phase insulin release during PE compared with the steady state.(min 3; 305+/-80 vs. 216+/-40pmol\l p=0.075). Finally, when relating the diabetic status to the general respiratory function we found a negative correlation between baseline FEV1 and glucose levels at 2h after OGTT during PE (r=-0.88, p=0.002).
CONCLUSION: In this pilot study we show that during PE patients with CF and normal glucose tolerance exhibited early latent diabetic glucose intolerance. As this hyperglycemia presents in the later parts of the OGTT it probably results from insufficient second phase insulin secretion during PE. The negative correlation observed here between the diabetic glucose tolerance and FEV1 indicate the need of interventional studies using insulin during PE in non-diabetic patients to determine its potential benefit on the outcome from recurrent PEs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20188638     DOI: 10.1016/j.jcf.2010.02.001

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  10 in total

1.  Plasma metabolomics in adults with cystic fibrosis during a pulmonary exacerbation: A pilot randomized study of high-dose vitamin D3 administration.

Authors:  Jessica A Alvarez; Elizabeth Y Chong; Douglas I Walker; Joshua D Chandler; Ellen S Michalski; Ruth E Grossmann; Karan Uppal; Shuzhao Li; Jennifer K Frediani; Rabindra Tirouvanziam; ViLinh T Tran; Vin Tangpricha; Dean P Jones; Thomas R Ziegler
Journal:  Metabolism       Date:  2017-02-11       Impact factor: 8.694

2.  Insulin signaling via the PI3-kinase/Akt pathway regulates airway glucose uptake and barrier function in a CFTR-dependent manner.

Authors:  Samuel A Molina; Hannah K Moriarty; Daniel T Infield; Barry R Imhoff; Rachel J Vance; Agnes H Kim; Jason M Hansen; William R Hunt; Michael Koval; Nael A McCarty
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-02-17       Impact factor: 5.464

3.  Hyperglycemia impedes lung bacterial clearance in a murine model of cystic fibrosis-related diabetes.

Authors:  William R Hunt; Susu M Zughaier; Dana E Guentert; Melissa A Shenep; Michael Koval; Nael A McCarty; Jason M Hansen
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-10-04       Impact factor: 5.464

4.  Glucose tolerance during pulmonary exacerbations in children with cystic fibrosis.

Authors:  John Widger; Mark R Oliver; Michele O'Connell; Fergus J Cameron; Sarath Ranganathan; Phil J Robinson
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

5.  Hospital versus home treatment of respiratory exacerbations in cystic fibrosis.

Authors:  Moran Lavie; Daphna Vilozni; Gil Sokol; Raz Somech; Amir Szeinberg; Ori Efrati
Journal:  Med Sci Monit       Date:  2011-12

6.  Drug treatments for managing cystic fibrosis-related diabetes.

Authors:  Gary M Onady; Adrienne Stolfi
Journal:  Cochrane Database Syst Rev       Date:  2020-10-19

7.  Acute hyperglycaemia in cystic fibrosis pulmonary exacerbations.

Authors:  Lina Merjaneh; Demet Toprak; Sharon McNamara; Laura Nay; Erin Sullivan; Margaret Rosenfeld
Journal:  Endocrinol Diabetes Metab       Date:  2020-11-30

8.  Association between Lung Function and New-Onset Diabetes Mellitus in Healthy Individuals after a 6-Year Follow-up.

Authors:  Hwa Young Lee; Juyoung Shin; Hyunah Kim; Seung-Hwan Lee; Jae-Hyoung Cho; Sook Young Lee; Hun-Sung Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2021-12-13

9.  Practical aspects of diabetes technology use: Continuous glucose monitors, insulin pumps, and automated insulin delivery systems.

Authors:  Brynn E Marks; Kristen M Williams; Jordan S Sherwood; Melissa S Putman
Journal:  J Clin Transl Endocrinol       Date:  2021-12-04

Review 10.  Circulating biomarkers of antioxidant status and oxidative stress in people with cystic fibrosis: A systematic review and meta-analysis.

Authors:  Adam J Causer; Janis K Shute; Michael H Cummings; Anthony I Shepherd; Mathieu Gruet; Joseph T Costello; Stephen Bailey; Martin Lindley; Clare Pearson; Gary Connett; Mark I Allenby; Mary P Carroll; Thomas Daniels; Zoe L Saynor
Journal:  Redox Biol       Date:  2020-01-23       Impact factor: 11.799

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.